New drug SAR441255 tested in humans for first time
NCT ID NCT04521738
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested a single dose of a new drug called SAR441255 in 48 healthy, lean to overweight adults. The main goal was to check safety and how the body processes the drug. Researchers also looked at effects on blood sugar and insulin levels. This is a first step to see if the drug might help with weight or diabetes in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAR441255
- What this could lead to
- If successful, this could point toward a new treatment for diabetes or weight management.
- What could go wrong
- This is a very early Phase 1 trial with only 48 participants, so it's mainly checking safety. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site number 8400001
Knoxville, Tennessee, 37920, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can a Two-Drug combo tip the scales against obesity?
- Does when you eat carbs and protein reshape blood sugar control?
- Can a weekly shot keep metabolism from slowing after weight loss?
- Can music lessons rewire Teens' social media habits?
- Can Early-Life factors steer preterm and term infant health?